NASDAQ · Analyst Forecast

AnaptysBio, Inc. (ANAB) Stock Forecast & Price Target

$45.61 NASDAQ: ANAB Market Cap $1.36B

Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 16, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering AnaptysBio, Inc. (ANAB), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For AnaptysBio, Inc., analysts forecast revenue rising from $205.27M in 2025 to $408.56M in 2030; the average estimate for 2030 earnings per share is $8.21; with published estimates ranging from $5.47 to $10.70; 9 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$45.61
Consensus targetThe average of the price targets analysts have published.$81.00
Median targetThe middle target, less affected by a single outlier.$79.50
Highest targetThe most optimistic published target.$95.00
Lowest targetThe most pessimistic published target.$70.00
Difference from priceHow far the consensus target sits from today’s price.+77.6%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2025$153.50M$205.27M$234.08M9
2026$108.57M$146.09M$180.13M1
2027$192.91M$259.58M$320.07M4
2028$240.29M$304.49M$400.29M5
2029$256.29M$344.86M$425.23M2
2030$303.64M$408.56M$503.78M2

Earnings per share forecast

YearLowAverageHighAnalysts
2025−$2.11−$0.96−$0.299
2026$3.17$4.76$6.201
2027$5.16$7.75$10.104
2028$4.96$7.04$12.705
2029$5.38$8.08$10.522
2030$5.47$8.21$10.702

AnaptysBio, Inc. (ANAB) forecast — frequently asked questions

What is the analyst price target for AnaptysBio, Inc.?

Analysts covering AnaptysBio, Inc. (ANAB) have a consensus price target of $81.00, 77.6% above the current price of $45.61. Published targets range from $70.00 to $95.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for AnaptysBio, Inc.'s earnings?

The average analyst estimate for AnaptysBio, Inc. (ANAB) earnings per share in 2030 is 8.21, with individual estimates between 5.47 and 10.70.

How much revenue is AnaptysBio, Inc. expected to make?

Analysts forecast AnaptysBio, Inc. (ANAB) revenue of $408.56M in 2030, based on 2 published estimates.

How many analysts cover ANAB?

9 analysts contribute estimates for AnaptysBio, Inc. (ANAB). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.